• Health & Medicine

Four new cancer drugs approved on NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved 4 new cancer drugs for use on the NHS in Scotland to treat some lung, breast and prostate cancers. The Scottish Medicines Consortium (SMC) has approved 4 new cancer drugs for use on the NHS in Scotland to treat some lung, breast and prostate cancers.

13 November 2020

• Health & Medicine

Prostate cancer hormone therapy not recommended for NHS in England

A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer. A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.

26 June 2020

• Health & Medicine

Breast and ovarian cancer drug effective in advanced prostate cancer

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer. A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.

1 May 2020

• Health & Medicine

Hormone therapy now available for newly diagnosed prostate cancer in Scotland 

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.   A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

20 January 2020

• Health & Medicine

Prostate cancer MRI scans: is the NHS ready?

All men with suspected prostate cancer should be offered a specialist MRI scan, before a biopsy. That's the new recommendation, but is the NHS ready? All men with suspected prostate cancer should be offered a specialist MRI scan, before a biopsy. That's the new recommendation, but is the NHS ready?

9 May 2019

• Health & Medicine

Prostate cancer hormone therapy rejected on NHS in England

A prostate cancer drug won’t be offered on the NHS any earlier in the treatment plans of patients living with the disease in England. A prostate cancer drug won’t be offered on the NHS any earlier in the treatment plans of patients living with the disease in England.

5 April 2019

• Health & Medicine

Clinical trial launches to develop breath test for multiple cancers

Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage. Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage.

2 January 2019

• Health & Medicine

Specialist MRI scans recommended to help diagnose prostate cancer on NHS

A type of specialist MRI scan has been recommended as one of the first tests for diagnosing people with suspected prostate cancer A type of specialist MRI scan has been recommended as one of the first tests for diagnosing people with suspected prostate cancer

13 December 2018

• Health & Medicine

Prostate cancer radiotherapy could have benefits even after the disease has spread

Trial finds prostate radiotherapy plus standard treatment improves survival for some men whose prostate cancer has spread, which could help thousands in the UK. Trial finds prostate radiotherapy plus standard treatment improves survival for some men whose prostate cancer has spread, which could help thousands in the UK.

21 October 2018

• Health & Medicine

Cancer trial shows treating the prostate with radiotherapy improves survival

Treating the prostate with radiotherapy alongside standard treatment led to a 11 per cent* increase in survival for some men with advanced prostate cancer. Treating the prostate with radiotherapy alongside standard treatment led to a 11 per cent* increase in survival for some men with advanced prostate cancer.

21 October 2018

• Health & Medicine

Prostate cancer drug given initial ‘no’ for NHS in England

The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England. The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England.

7 June 2018